Literature DB >> 7265453

Pulmonary toxicity of antineoplastic drugs.

G Batist, J L Andrews.   

Abstract

Pulmonary toxicity caused by antineoplastic drugs is becoming a more frequently recognized entity, and the number of drugs known or suspected of causing this disease is steadily increasing. In general, the initial clinical appearance includes both constitutional signs of malaise and fever, as well as pulmonary complaints. Some clinical signs may suggest a particular drug as the cause. The pathological condition also is generally nonspecific, but some clues may be present histologically that help define the causal agent. This is a review of the antineoplastic drugs that are associated with pulmonary toxicity. Clinical, laboratory, and pathological data are presented as useful information for practicing physicians. Although therapeutic maneuvers are limited, these are discussed with regard to each drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7265453

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

1.  Cyclophosphamide-induced pulmonary toxicity.

Authors:  D W Siemann; L Macler; D P Penney
Journal:  Br J Cancer Suppl       Date:  1986

2.  NMR study of the effects of some bleomycin C-termini on the structure of a DNA hairpin with the 5'-GC-3' binding site.

Authors:  Teresa E Lehmann; Sally A Murray; Azure D Ingersoll; Teresa M Reilly; Shelby E Follett; Kevin E Macartney; Mark H Harpster
Journal:  J Biol Inorg Chem       Date:  2016-11-17       Impact factor: 3.358

3.  Lung pseudometastases due to vinblastine toxicity.

Authors:  F Franchi; P Seminara; G F Gualdi
Journal:  Klin Wochenschr       Date:  1984-11-02

Review 4.  Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications.

Authors:  D S Klein; P R Wilds
Journal:  Can Anaesth Soc J       Date:  1983-07

5.  Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide.

Authors:  D A Burke; J C Stoddart; M K Ward; C G Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11

6.  Interaction of Zn(II)bleomycin-A2 and Zn(II)peplomycin with a DNA hairpin containing the 5'-GT-3' binding site in comparison with the 5'-GC-3' binding site studied by NMR spectroscopy.

Authors:  Shelby E Follett; Azure D Ingersoll; Sally A Murray; Teresa M Reilly; Teresa E Lehmann
Journal:  J Biol Inorg Chem       Date:  2017-07-26       Impact factor: 3.358

7.  Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Mol Cell Biochem       Date:  1995-01-12       Impact factor: 3.396

8.  Cyclophosphamide induced early biochemical changes in lung lavage fluid and alterations in lavage cell function.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Lung       Date:  1994       Impact factor: 2.584

Review 9.  Busulfan-Induced Lung Injury in Pediatric Oncology Patients-Review of the Literature with an Illustrative Case.

Authors:  Nusa Matijasic; Aleksandra Bonevski; Visnja Tokic Pivac; Ivan Pavic
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-09-17       Impact factor: 1.349

10.  [Bleomycin-induced pulmonary infiltrations in the treatment of testicular cancer].

Authors:  C Clemm; R Hartenstein; B Mayr; W Wilmanns
Journal:  Klin Wochenschr       Date:  1984-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.